WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H122824
CAS#: 178961-24-5
Description: 264W94 is a IBAT inhibitor with IC50 = 180 nM.
Hodoodo Cat#: H122824
Name: 264W94
CAS#: 178961-24-5
Chemical Formula: C23H31NO4S
Exact Mass: 417.20
Molecular Weight: 417.560
Elemental Analysis: C, 66.16; H, 7.48; N, 3.35; O, 15.33; S, 7.68
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: 264W94; 8GYW8T88JI; CHEMBL332370
IUPAC/Chemical Name: (3R,5R)-3-butyl-3-ethyl-7,8-dimethoxy-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine 1,1-dioxide
InChi Key: CKFWDLFFXXVSBJ-DHIUTWEWSA-N
InChi Code: InChI=1S/C23H31NO4S/c1-5-7-13-23(6-2)16-29(25,26)21-15-20(28-4)19(27-3)14-18(21)22(24-23)17-11-9-8-10-12-17/h8-12,14-15,22,24H,5-7,13,16H2,1-4H3/t22-,23-/m1/s1
SMILES Code: COC1=C(OC)C=C(C2=C1)[C@@H](C3=CC=CC=C3)N[C@](CC)(CCCC)CS2(=O)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 417.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Root C, Smith CD, Sundseth SS, Pink HM, Wilson JG, Lewis MC. Ileal bile acid
transporter inhibition, CYP7A1 induction, and antilipemic action of 264W94. J
Lipid Res. 2002 Aug;43(8):1320-30. PMID: 12177176.
2: Chen L, Yao X, Young A, McNulty J, Anderson D, Liu Y, Nystrom C, Croom D,
Ross S, Collins J, Rajpal D, Hamlet K, Smith C, Gedulin B. Inhibition of apical
sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J
Physiol Endocrinol Metab. 2012 Jan 1;302(1):E68-76. doi:
10.1152/ajpendo.00323.2011. Epub 2011 Sep 20. PMID: 21934041.
3: Saveleva EE, Tyutrina ES, Nakanishi T, Tamai I, Salmina AB. Ingibitory
natriĭ-zavisimogo perenoschika zhelchnykh kislot (ASBT) kak perspektivnye
lekarstvennye sredstva [The inhibitors of the apical sodium-dependent bile acid
transporter (ASBT) as promising drugs]. Biomed Khim. 2020 May;66(3):185-195.
Russian. doi: 10.18097/PBMC20206603185. PMID: 32588824.
4: Wu Y, Aquino CJ, Cowan DJ, Anderson DL, Ambroso JL, Bishop MJ, Boros EE, Chen
L, Cunningham A, Dobbins RL, Feldman PL, Harston LT, Kaldor IW, Klein R, Liang
X, McIntyre MS, Merrill CL, Patterson KM, Prescott JS, Ray JS, Roller SG, Yao X,
Young A, Yuen J, Collins JL. Discovery of a highly potent, nonabsorbable apical
sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of
type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114. doi:
10.1021/jm400459m. Epub 2013 Jun 6. PMID: 23678871.